Note: this article is provided by ONU Healthwise Pharmacy.
A new migraine medication is hitting the market.
The US Food and Drug Administration (FDA) has approved Reyvow (lasmiditan) to treat migraines.
Migraines are estimated to affect more than 10 percent of people around the world.
Lasmiditan, available in tablet form, has been approved for adults with migraines with or without aura.
Aura is a sensory phenomenon or visual disturbance. An aura can occur as flashing lights, zig-zag lines or temporary vision loss. Auras typically affect around one-third of people who have migraines.
Note: this article is provided by ONU Healthwise Pharmacy.
For Breast Cancer Awareness Month, we're debunking four common mammogram myths.
Mammograms are low-dose X-ray pictures of the breast. Because mammography can detect breast cancer tumors before they can be felt, screening is very important for early detection. And early breast cancer detection has been linked to higher chances of survival. Speak with your doctor about how often you should be screened for breast cancer. For more information on performing a breast self-exam and detecting breast changes, check out Detecting Breast Cancer Early.
FDA continues to warn consumers of potential risks of vaping
Posted by LizGH on Sunday, October 20, 2019
Note: this article is provided by ONU Healthwise Pharmacy.
Health officials continue to investigate e-cigarettes as the number of reported respiratory problems tied to vaping continues to rise.
Recently, the US Food and Drug Administration (FDA) issued a warning about a possible risk of respiratory issues tied to e-cig products. At the end of August, the FDA stated that 25 states had reported 215 possible cases of such issues.
The FDA said it is working closely with the Centers for Disease Control and Prevention (CDC) and other government partners to investigate recent severe lung injuries and deaths tied to vaping.
FDA approves Rybelsus (semaglutide) to treat type 2 diabetes
Posted by LizGH on Sunday, October 13, 2019
Note: this article is provided by ONU Healthwise Pharmacy.
The US Food and Drug Administration (FDA) has approved a new diabetes medication.
This new approval is found under the names Rybelsus (brand name) and semaglutide (active ingredient). The FDA approved semaglutide to treat adults with type 2 diabetes in combination with diet and exercise.
This new drug is available in tablet form and is to be taken once a day. It is to be taken at least 30 minutes before you consume any food, beverage or other medication for the day. Rybelsus needs to be taken with no more than 4 ounces of plain water.
FDA approves pre-measured Gvoke (glucagon) to treat severe low blood sugar
Posted by LizGH on Sunday, October 6, 2019
Note: this article is provided by ONU Healthwise Pharmacy.
Treating severe low blood sugar doesn't have to be complex and overwhelming. And a newly approved treatment may make things even easier.
The US Food and Drug Administration (FDA) has approved Gvoke (glucagon) to be used in emergency instances of severe low blood sugar (hypoglycemia). This new approval, intended for those over the age of 2 who have diabetes, includes the following: